Fig. 5

Durable remission by combination therapy with TAK-981 and trametinib in mouse models. A NCI-H2122 xenograft mouse model treated with vehicle (control), trametinib (0.6 mg/kg, p.o., daily), TAK-981 (25 mg/kg, i.p., twice/week), or both drugs in combination at the same dose. Tumor volumes were plotted over time from treatment initiation (n ≥ 6 per group; mean ± s.e.m.). B Waterfall plots showing the percentage change in tumor volume (relative to the initial volume) for individual NCI-H2122 tumors after 18 days of treatment. C, D Xenograft mouse models using HCT116 or MIA PaCa-2 cells treated with vehicle (control) or trametinib (0.6 mg/kg, p.o., daily) plus TAK-981 (25 mg/kg, i.p., twice a week). Tumor volumes were plotted over time from treatment initiation (n ≥ 6 per group; mean ± s.e.m.)